Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 26Neoplasm Metastasis 7Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Thyroid Neoplasms 1Recurrence Free Survival 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Histiocytosis 1Glioma 1Fallopian Tube Neoplasms 1Erythema 1Endometrial Neoplasms 1Edema 1Dihydropyrimidine Dehydrogenase Deficiency 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1

Interventions

Gemcitabine 5Taxes 3Albumin-Bound Paclitaxel 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2Oxaliplatin 2Losartan 2Leucovorin 2Irinotecan 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tocilizumab 1selicrelumab 1niraparib 1durvalumab 1dehydroftorafur 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiation 1Panitumumab 1Pancreaticoduodenectomy 1PEGPH20 1Optical Imaging 1Nivolumab 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × Panitumumab × 1 year × Clear all
NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Stanford University

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡